Searchable abstracts of presentations at key conferences in endocrinology

ea0056p836 | Pituitary - Clinical | ECE2018

Early postsurgery cortisol after transphenoidal surgery to predict adrenal insufficiency one year posturgery

Gonzalez Molero Inmaculada , Doulatram Viyey , Maraver Silvia , Gonzalo Marin Montse , Abuin Jose , Ruiz Garcia Ignacio , Angel Arraez Miguel , Tinahones Francisco , Olveira Gabriel

Aim: To assess a perioperative glucocorticoid protocol in transsphenoidal surgery (TSS)and the performance of early post-TSS 08:00 cortisol measurement to detect/exclude secondary adrenal insufficiency.Methods: We selected patients undergoing TSS.In patients with no cushing disease, we checked cortisol/Synachten presurgery, measured 3° postoperative 0800 a.m. cortisol(after 24 h without corticoids) and cortisol/Synachten 3-6 months post-surgery. We ...

ea0035oc12.2 | Pituitary Basic | ECE2014

Differential in vitro response to octreotide and pasireotide in normal and tumoral primary pituitary cell cultures

Ibanez-Costa Alejandro , Gahete Manuel David , Jimenez-Reina Luis , Rivero-Cortes Esther , Lopez-Sanchez Laura Maria , Galvez Maria Angeles , de la Riva Andres , Benito-Lopez Pedro , Venegas-Moreno Eva , Angel Japon Miguel , Moreno Alberto , Garcia-Arnes Juan Antonio , Maraver-Selfa Silvia , Angel Arraez Miguel , Leal-Cerro Alfonso , Schmid Herbert A. , Tinahones Francisco J. , Soto-Moreno Alfonso , Castano Justo P. , Luque Raul M.

Somatostatin analogs (SSA) are a first-line treatment for pituitary adenomas (PA). Indeed, multi-receptor targeting SSA such as octreotide and pasireotide are being successfully used to control hormone secretion and/or tumor growth. Unfortunately, many PA escape from SSA-therapy, which could be related to somatostatin receptor (sst) presence, abundance, availability and/or signaling. In order to better define the molecular/cellular features associated to octreotide and pasireo...